


Status: Currently Official on 17-Feb-2025
Official Date: Official as of 01-Jul-2020
Document Type: USP Monographs
DocId: GUID-428112B4-F69F-4615-AD6D-B089938BEC1F_8_en-US
DOI: https://doi.org/10.31003/USPNF_M6400_08_01
DOI Ref: x10lg

© 2025 USPC
Do not distribute

Atropine Sulfate

Change to read:



$(C_{17}H_{23}NO_3)_2 \cdot H_2SO_4 \cdot H_2O$ ▲694.84▲ (ERR 1-Jul-2020)
Anhydrous 676.82

Benzeneacetic acid, α -(hydroxymethyl)-, 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester, *endo*-(±)-, sulfate (2:1) (salt), monohydrate;
1 α H,5 α H-Tropan-3- α -ol (±)-tropate (ester), sulfate (2:1) (salt) monohydrate CAS RN®: 5908-99-6; UNII: 03J5ZE7KA5.
Anhydrous CAS RN®: 55-48-1; UNII: KAE4PSB0Z3.

DEFINITION

Atropine Sulfate contains NLT 98.0% and NMT 102.0% of atropine sulfate $[(C_{17}H_{23}NO_3)_2 \cdot H_2SO_4]$, calculated on the anhydrous basis.

[CAUTION—Handle atropine sulfate with exceptional care, because it is highly potent.]

IDENTIFICATION

- **A. SPECTROSCOPIC IDENTIFICATION TESTS** (197), *Infrared Spectroscopy*: 197K or 197A
- **B. IDENTIFICATION TESTS—GENERAL** (191), *Chemical Identification Tests, Sulfate*
Sample solution: 50 mg/mL
Acceptance criteria: Meets the requirements
- **C.** The retention time of the major peak of the *Sample solution* corresponds to that of the *System suitability solution*, as obtained in the Assay.

ASSAY

• **PROCEDURE**

Buffer: 1.8 g/L of [monobasic potassium phosphate](#) and 2.5 g/L of [sodium 1-pentanesulfonate](#), adjusted with [phosphoric acid](#) to a pH of 2.5
Diluent: [Acetonitrile](#) and *Buffer* (20:80)
Solution A: [Acetonitrile](#) and *Buffer* (5:95)
Solution B: [Acetonitrile](#) and *Buffer* (80:20)
Mobile phase: See [Table 1](#).

Table 1

| Time (min) | Solution A (%) | Solution B (%) |
|------------|----------------|----------------|
| 0 | 92 | 8 |
| 11 | 79 | 21 |
| 15 | 46 | 54 |
| 15.1 | 92 | 8 |
| 20 | 92 | 8 |

[NOTE—The gradient was established on an HPLC system with a dwell volume of approximately 0.8 mL.]

System suitability solution: 1 μ g/mL of [USP Hyoscyamine Related Compound A RS](#) and 0.5 mg/mL of [USP Atropine Sulfate RS](#) in *Diluent*
Sensitivity solution: 0.25 μ g/mL of [USP Atropine Sulfate RS](#) in *Diluent*

Standard solution: 0.5 mg/mL of [USP Atropine Sulfate RS](#) in *Diluent*

Sample solution: 0.5 mg/mL of Atropine Sulfate in *Diluent*

Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

Mode: LC

Detector: UV 210 nm

Column: 4.6-mm × 15-cm; 3-μm packing [L1](#)

Column temperature: 50°

Flow rate: 2 mL/min

Injection volume: 5 μL

System suitability

Samples: *System suitability solution*, *Sensitivity solution*, and *Standard solution*

[NOTE—See [Table 2](#) for the relative retention times.]

Suitability requirements

Resolution: NLT 1.4 between hyoscyamine related compound A and atropine, *System suitability solution*

Tailing factor: 0.8–1.8 for atropine, *System suitability solution*

Relative standard deviation: NMT 0.73%, *Standard solution*

Signal-to-noise ratio: NLT 10 for atropine, *Sensitivity solution*

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of atropine sulfate [(C₁₇H₂₃NO₃)₂ · H₂SO₄] in the portion of Atropine Sulfate taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response of atropine from the *Sample solution*

r_S = peak response of atropine from the *Standard solution*

C_S = concentration of [USP Atropine Sulfate RS](#) in the *Standard solution* (mg/mL)

C_U = concentration of Atropine Sulfate in the *Sample solution* (mg/mL)

Acceptance criteria: 98.0%–102.0% on the anhydrous basis

IMPURITIES

• [RESIDUE ON IGNITION \(281\)](#): NMT 0.2%

• **ORGANIC IMPURITIES**

Buffer, Diluent, Solution A, Solution B, Mobile phase, System suitability solution, Sensitivity solution, Standard solution, Sample solution, Chromatographic system, and System suitability: Proceed as directed in the Assay.

Analysis

Sample: *Sample solution*

Calculate the percentage of each impurity in the portion of Atropine Sulfate taken:

$$\text{Result} = (r_U/r_T) \times (1/F) \times 100$$

r_U = peak response of each impurity from the *Sample solution*

r_T = sum of all the peak responses from the *Sample solution*

F = relative response factor for each impurity (see [Table 2](#))

Acceptance criteria: See [Table 2](#). The reporting threshold is 0.05%.

Table 2

| Name | Relative Retention Time | Relative Response Factor | Acceptance Criteria, NMT (%) |
|-----------------------------------|-------------------------|--------------------------|------------------------------|
| Tropic acid ^a | 0.56 | 2.1 | 0.2 |
| 7-Hydroxyhyoscyamine ^b | 0.66 | 1.0 | 0.2 |
| Scopolamine ^c | 0.72 | 1.0 | 0.2 |

| Name | Relative Retention Time | Relative Response Factor | Acceptance Criteria, NMT (%) |
|--------------------------------------|-------------------------|--------------------------|------------------------------|
| 6-Hydroxyhyoscyamine ^d | 0.75 | 1.0 | 0.2 |
| Hyoscyamine related compound A | 0.97 | 1.2 | 0.3 |
| Atropine | 1.0 | 1.0 | — |
| Littorine ^e | 1.13 | 1.2 | 0.2 |
| Apoatropine ^f | 1.60 | 2.0 | 0.2 |
| Any individual, unspecified impurity | — | 1.0 | 0.1 |
| Total impurities | — | — | 0.5 |

^a 3-Hydroxy-2-phenylpropanoic acid; also known as (2*RS*)-3-Hydroxy-2-phenylpropanoic acid.

^b (1*S*,3*R*,5*S*)-6-Hydroxy-8-methyl-8-azabicyclo[3.2.1]oct-3-yl (S)-3-hydroxy-2-phenylpropanoate; also known as (1*S*,3*R*,5*S*,6*RS*)-6-Hydroxy-8-methyl-8-azabicyclo[3.2.1]oct-3-yl (2*S*)-3-hydroxy-2-phenylpropanoate.

^c (S)-(1*R*,2*R*,4*S*,5*S*,7*s*)-9-Methyl-3-oxa-9-azatricyclo[3.3.1.0^{2,4}]nonan-7-yl 3-hydroxy-2-phenylpropanoate; also known as (S)-(1*R*,2*R*,4*S*,5*S*,7*s*)-9-Methyl-3-oxa-9-azatricyclo[3.3.1.0^{2,4}]non-7-yl (2*S*)-3-hydroxy-2-phenylpropanoate.

^d (1*R*,3*S*,5*R*)-6-Hydroxy-8-methyl-8-azabicyclo[3.2.1]octan-3-yl (S)-3-hydroxy-2-phenylpropanoate; also known as (1*R*,3*S*,5*R*,6*RS*)-6-Hydroxy-8-methyl-8-azabicyclo[3.2.1]oct-3-yl (2*S*)-3-hydroxy-2-phenylpropanoate.

^e (1*R*,3*r*,5*S*)-8-Methyl-8-azabicyclo[3.2.1]octan-3-yl 2-hydroxy-3-phenylpropanoate; also known as (1*R*,3*r*,5*S*)-8-Methyl-8-azabicyclo[3.2.1]oct-3-yl (2*RS*)-2-hydroxy-3-phenylpropanoate.

^f (1*R*,3*r*,5*S*)-8-Methyl-8-azabicyclo[3.2.1]octan-3-yl 2-phenylacrylate; also known as (1*R*,3*r*,5*S*)-8-Methyl-8-azabicyclo[3.2.1]oct-3-yl 2-phenylpropenoate.

SPECIFIC TESTS

- [OPTICAL ROTATION \(781S\)](#), [Procedures](#), [Specific Rotation](#)

Sample solution: 0.1 g/mL of Atropine Sulfate in water

Temperature: 20°

Path length: 1.0 or 2.0 dm

Acceptance criteria: Between -0.50° and +0.05°

- [WATER DETERMINATION \(921\)](#), [Method I](#): NMT 4.0%

ADDITIONAL REQUIREMENTS


- **PACKAGING AND STORAGE:** Preserve in tight, light-resistant containers.

- [USP REFERENCE STANDARDS \(11\)](#).

[USP Atropine Sulfate RS](#)

[USP Hyoscyamine Related Compound A RS](#)

Norhyoscyamine sulfate; (1*R*,3*r*,5*S*)-8-Azabicyclo[3.2.1]octan-3-yl (S)-3-hydroxy-2-phenylpropanoate sulfate (2:1).



Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

| Topic/Question | Contact | Expert Committee |
|----------------------------|---|---------------------------|
| ATROPINE SULFATE | Documentary Standards Support | SM42020 Small Molecules 4 |
| REFERENCE STANDARD SUPPORT | RS Technical Services RSTECH@usp.org | SM42020 Small Molecules 4 |

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 43(5)

Current DocID: GUID-428112B4-F69F-4615-AD6D-B089938BEC1F_8_en-US

DOI: https://doi.org/10.31003/USPNF_M6400_08_01

DOI ref: [x10lg](#)

OFFICIAL